2025年11月10日起，我国在现行国家免疫规划疫苗基础上，将HPV疫苗纳入国家免疫规划。此前，本市 以落实2025年民生实事项目的方式，为2025年9月新入学的初一在校女生免费接种HPV疫苗。针对两项 政策如何衔接的问题，市疾控局表示，2025年9月新入学的初一在校女生，如已接种本市民生实事HPV 疫苗第1剂，可继续使用该疫苗完成全程接种。目前第1剂接种已结束。未接种过民生实事疫苗且符合国 家免疫规划接种条件的适龄女生，可选择国家免疫规划HPV疫苗进行接种。 本报讯（记者 孙乐琪）市疾控局昨天介绍，本市已全面启动适龄女生国家免疫规划HPV（人乳头瘤病 毒）疫苗接种，为满13周岁女生免费接种HPV疫苗。 市疾控局介绍，2011年11月10日以后出生的满13周岁女孩可免费接种2剂次双价HPV疫苗，2剂之间的接 种间隔为6个月。如果受种者未按照常规免疫程序完成2剂次疫苗接种，应在18岁之前尽早补齐2剂次。 第2剂与第1剂接种间隔6个月，间隔期最好不要超过一年。 适龄女生可根据所在学校安排，参加校内集中接种，也可通过拨打预防接种门诊电话、现场登记、"京 通"小程序、"首都疫苗服务" App等方式预约。预防接种门诊信 ...

Market Overview - The U.S. stock market closed on December 25, 2025, for Christmas, following a week where major indices reached all-time highs, with normal trading resuming on December 26, 2025 [1] - On Christmas Eve, the S&P 500 rose 0.3% to close at 6,932.05, marking a year-to-date increase of over 17%, while the Dow Jones Industrial Average climbed 0.6% to 48,731.16, and the Nasdaq Composite edged up 0.2% to 23,613.31, contributing to a 21.6% year-to-date advance [3] Futures and Premarket Activity - Futures contracts for major indices were down approximately 0.1% on December 24, 2025, despite a positive sentiment indicated by a slight gain of 0.09% in the US500 index on December 25, reaching 6,938 points [2] Economic Outlook - Key economic indicators to watch include the Federal Reserve Bank of New York's Staff Nowcast on December 26, followed by reports on international trade, pending home sales, and manufacturing surveys on December 29 [4] - The Federal Reserve recently trimmed its benchmark interest rate to a range of 3.5%-3.75%, with analysts expecting rates to remain steady at the January meeting due to mixed economic data [5] Corporate Highlights - Dynavax Technologies saw a 38.2% surge in shares following Sanofi's announcement of a $2.2 billion acquisition [6] - Nike's stock rose 4.6% after Apple CEO Tim Cook purchased nearly $3 million worth of Nike shares [6] - Nvidia shares dipped 0.3% on Christmas Eve but have a year-to-date return of 30.2%, briefly surpassing a $5 trillion market cap in October [10] - Microsoft achieved a 15.6% gain in 2025, with shares trading near $485, leveraging its partnership with OpenAI [10] - ServiceNow confirmed a $7.75 billion acquisition of Armis, although its stock experienced an 11.5% pullback recently [10] - Caterpillar Inc. saw over 60% growth in 2025, driven by its Energy & Transportation segment [10] - Goldman Sachs shares increased by 61% in 2025, identifying potential buying opportunities in the tech sector for 2026 [10] - Eli Lilly shares climbed 40% this year, while Novo Nordisk shares fell nearly 40% due to competition in the weight-loss medication market [10] - Marvell Technology Inc. gained 3.4% on the Nasdaq on December 24 [10] Commodity Markets - Gold and silver futures reached new all-time highs, with gold at $4,555 and silver at $72.75 per ounce [10] - WTI crude oil futures remained stable, trading near $58.40 per barrel [10]

一是积极接种流感疫苗。接种流感疫苗是预防流感最经济、有效的手段，可以显著降低接种者罹患 流感和发生重症的风险。推荐6月龄及以上且没有接种禁忌的人都应该接种流感疫苗。优先推荐60岁及 以上老年人、儿童、慢性病患者、婴儿的家庭成员和看护人员等重点人群，托幼机构、中小学校、医疗 机构、养老机构、监管场所等重点场所的人群及时接种。接种流感疫苗的常见不良反应通常是轻微的， 大家无需过于担心。有些地方已经面向中小学生和老年人提供免费的流感疫苗接种，起到了保护效果。 如果能够达到较高的接种率，则人群的保护效果会更加好。 当前流感疫苗的接种服务便利性越来越可及，许多社区卫生服务中心、乡镇卫生院都提供了周末预 约接种、延时接种等等，希望大家能够尽快接种疫苗，用预防而非患病后再治疗的手段是最合适的，也 是最值得提倡的。 国家卫生健康委19日召开新闻发布会，介绍时令节气与健康(冬至)有关情况。江苏省疾病预防控制 中心主任医师霍翔表示，低温寒潮发生的时间往往与流感等呼吸道传染病流行季节重叠。公众需要从以 下方面做好防护： 二是要养成良好的卫生习惯。咳嗽、打喷嚏的时候要用纸巾或者用臂弯遮住口鼻，注意手卫生，避 免用不洁的手触摸眼、鼻、 ...

Core Insights - Valneva SE announced positive final antibody persistence and safety data for its Phase 2 clinical trial of the chikungunya vaccine IXCHIQ, showing promising results in 304 children twelve months post-vaccination [1][2][3] Vaccine Efficacy and Safety - The full dose of IXCHIQ elicited a 94.7% seroresponse rate in chikungunya virus-naïve children at Day 360, indicating a strong immune response [3][4] - The vaccine was well tolerated across all age groups tested, with no safety concerns identified [3][4][9] - The trial results align with previous data reported in January and June 2025, confirming the robustness of the immune response and safety profile [2][5] Future Development Plans - The company plans to initiate a Phase 3 study in children after gathering additional real-world experience in the adolescent population, emphasizing the importance of safety [5][9] - The selection of the full dose for future trials is supported by the favorable immune response and safety data observed [4][9] Chikungunya Context - Chikungunya has seen a significant rise in cases globally, with Brazil reporting over one million cases from January 2019 to July 2024, highlighting the urgent need for effective vaccination [5][7] - The World Health Organization has identified chikungunya as a major public health problem, with the disease affecting over 110 countries since its re-emergence [6][7] Trial Details - The Phase 2 trial (VLA1553-221) was a multi-center, randomized, observer-blinded study involving 304 healthy children aged one to eleven years, conducted in the Dominican Republic and Honduras [8][10] - Participants were randomized to receive either a full dose, a half dose, or an active control, with the primary focus on evaluating safety and immunogenicity [8][10]

Core Insights - Shares of major vaccine manufacturers including Moderna, BioNTech, Pfizer, Novavax, and Vaxcyte experienced declines following the FDA's announcement of new stringent vaccine requirements [1][7] Regulatory Changes - Dr. Vinay Prasad, head of the FDA's CBER, acknowledged in an internal memo that "COVID-19 vaccines have killed American children," citing at least 10 child deaths linked to COVID-19 vaccinations and myocarditis concerns [2][3] - The FDA plans to revise guidelines for various vaccines, including stricter safety requirements for vaccines administered to pregnant women and a reevaluation of the annual influenza vaccine framework [4][5] Market Reaction - Following the news, Moderna's shares fell by 7%, BioNTech by 6%, Pfizer by nearly 2%, Novavax by 5%, and Vaxcyte by over 8% [7] - Investor concerns are heightened regarding the potential for increased anti-vaccine sentiment due to the FDA's stricter regulatory focus [8] Industry Context - The developments align with the current leadership at the Department of Health and Human Services under Robert F. Kennedy Jr., known for his skepticism towards vaccines, raising questions about the independence of public health decision-making [9][11] - The upcoming CDC advisory committee meeting scheduled for December 4-5, 2025, will discuss the childhood vaccine schedule and hepatitis B shot, adding further pressure on vaccine manufacturers [8]

Market Overview - The equity markets are experiencing a general malaise, with major indices showing declines on the first trading day of December [1][6] - The S&P 500 is down approximately 0.5%, the Nasdaq indices are down about 0.4%, and the Dow Jones Industrial Average is down roughly 0.9% [6] - The Russell 2000 index is the laggard, down 1.3% [7] Treasury Yields - U.S. Treasury yields are rising, with the ten-year yield above 4%, influenced by developments in Japan and expectations of a Federal Reserve interest rate increase [2][23] - The sell-off in Japanese debt due to inflation concerns has contributed to the increase in U.S. yields [23] Cryptocurrency Market - The cryptocurrency market is facing significant declines, with Bitcoin down 6.3%, Ether down 8.7%, and XRP down 7.5%, marking a more than 30% drop from Bitcoin's all-time high [3][4] Sector Performance - The energy sector is the top performer, up about 0.9%, while utilities are down approximately 2.4% and industrials down about 1.5% [7][8] - Notable gainers include Old Dominion Freight Line, which rose about 3.2%, and Nvidia, which gained nearly 5% following a $2 billion investment in Synopsys [9][11] Company News - BMO Capital Markets upgraded Old Dominion Freight Line to outperform, citing potential upside when the freight cycle turns, while slightly lowering the price target [10] - Nvidia's investment in Synopsys aims to integrate AI computing technology into chip design applications, enhancing collaboration between the two companies [11][12] - DoorDash shares increased by 3.6% after a major investor boosted their stake in the company [13] Regulatory Developments - Moderna shares fell by 7% following news of new FDA restrictions on vaccine approvals, which could limit vaccine availability [15][16] - Airbus shares declined by 3.2% due to quality issues with A320 fuselage panels, raising concerns about meeting earnings goals [18][19] Corporate Strategies - Disney is seeking an energy trader to manage power costs as major corporations become more strategic about energy management [24][25] - New York City has approved three casinos, including one by Steve Cohen, expanding his sports and gambling empire [27][28]

Market Overview - The A-share market showed overall strength, with the ChiNext Index rising over 3% at one point. The Shanghai Composite Index closed down 0.15% at 3864.18 points, while the Shenzhen Component Index rose 1.02% to 12907.83 points, and the ChiNext Index increased by 2.14% to 3044.69 points. The total trading volume in the Shanghai and Shenzhen markets reached 1.7973 trillion yuan [1] Consumer Sector - The consumer sector, led by retail stocks, saw significant late-session gains. Notable stocks such as Hai Xin Food and Kai Chun Co. reached their daily limit up. The Ministry of Industry and Information Technology and other departments issued a plan to enhance the adaptability of supply and demand in consumer goods, aiming for a noticeable optimization of the supply structure by 2027 and a high-quality development pattern by 2030 [2] AI Industry - CPO concept stocks and AI-related stocks remained active, with several companies like Chang Guang Hua Xin and Sai Wei Electronics hitting their daily limit up. Alibaba's CEO indicated a sustained demand for AI resources, predicting a supply-demand imbalance for the next three years. Alibaba's cloud revenue grew by 34% year-on-year, with AI-related product revenue increasing for nine consecutive quarters [4][5] Pharmaceutical Sector - The pharmaceutical sector experienced strong gains, particularly in innovative drugs and vaccine concepts. Companies like Yue Wannianqing and Huaren Health reached their daily limit up. The small nucleic acid drug field is gaining attention due to recent global advancements, with expectations for significant growth driven by technological breakthroughs and commercialization [7]

Novavax Conference Call Summary Company Overview - Novavax is recognized for its successful development of a highly efficacious COVID-19 vaccine using subunit protein nanoparticle technology combined with the Matrix-M adjuvant, which has also been utilized in a malaria vaccine developed by Serum Institute of India [4][5] Strategic Focus - The company is transitioning from a pandemic-focused entity to an endemic-based vaccine manufacturer, partnering with Sanofi to integrate its COVID-19 vaccine, Nuvaxovid, into Sanofi's portfolio of vaccines [5][6] - Novavax aims to reduce costs, strengthen its balance sheet, and advance its pipeline through partnerships, with a long-term goal of achieving profitability and diversified revenue streams [6][9] Partnership with Sanofi - The partnership with Sanofi is structured in layers, including commercialization of the COVID-19 vaccine, development of combination vaccines, and leveraging Matrix-M in Sanofi's portfolio [9][10] - The market for combination flu and COVID-19 vaccines could reach $8 billion annually, with Novavax eligible for up to $350 million in milestones and royalties ranging from high single digits to low teens [10][11] - Sanofi's 2026 season is expected to be the full launch year for the COVID-19 vaccine, with 2025 serving as a transition year for learning and marketing efforts [12][13] Financial Highlights - Novavax received a $70 million investment from Sanofi, $500 million upfront, and has the potential for $700 million in milestone payments [22][23] - In the current year, Novavax earned $225 million in milestones, with royalties expected to grow significantly as the partnership matures [23] Matrix-M Adjuvant - Matrix-M is positioned as a critical driver of innovation in the vaccine industry, with potential royalties of mid-single digits for up to 20 years on new vaccines developed using this adjuvant [25][26] - The global vaccine market is projected to grow from $57 billion in 2024 to over $75 billion by 2030, highlighting the significant opportunity for Matrix-M [25] Early Stage Pipeline - Novavax is exploring various early-stage vaccines targeting infectious diseases, including CDIF, shingles, RSV, and pandemic flu, with a focus on addressing unmet medical needs [38][39] - The company is also investigating the use of Matrix-M in oncology vaccines, collaborating with partners to explore its potential in this area [34][41] Market Potential - The oncology vaccine market is valued at over $40 billion, contributing to a combined market potential exceeding $100 billion when combined with the vaccine market [34] - Novavax's approach includes leveraging AI and machine learning to enhance immune responses and develop tailored vaccines for specific needs [33][41] Conclusion - Novavax is strategically positioned to capitalize on its innovative technologies and partnerships, with a clear focus on expanding its vaccine portfolio and driving long-term value creation through diversified revenue streams and cost management [6][23][25]

Danish vaccine maker Bavarian Nordic said on Thursday Luc Debruyne will step down as chair, days after a takeover attempt by Nordic Capital and Permira collapsed. ...

Core Viewpoint - Novavax, Inc. is recognized as a promising long-term biotechnology investment, with Cantor Fitzgerald initiating coverage with an Overweight rating and a price target of $18 [1] Group 1: Company Strategy and Developments - Novavax is transitioning from direct commercialization to a licensing model, focusing on revenue generation through partnerships related to its Matrix-M adjuvant and vaccine portfolio [2] - The company has transferred its COVID-19 vaccine, Nuvaxoid, to Sanofi, granting Sanofi full responsibility for commercial and regulatory activities in the EU, and is set to receive a $25 million milestone payment [2][3] - Novavax is entitled to additional future milestone payments, including a $75 million payment upon Sanofi's technology transfer of its manufacturing process, and could receive up to an additional $350 million in future milestone payments [3] Group 2: Product and Technology - Novavax develops innovative vaccines using protein-based technology, specifically recombinant nanoparticle technology and its proprietary Matrix-M adjuvant to enhance immune response [3]